Engineering strategies to optimise adoptive cell therapy in ovarian cancer

Area of Science:

• Oncology
• Immunotherapy

Background:

• Ovarian cancer is a leading cause of death in women, with high rates of relapse and treatment resistance.
• Current targeted therapies like PARPi have limitations, necessitating novel treatment strategies.
• Adoptive cell therapy (ACT) utilizes autologous immune cells for cancer elimination.

Purpose of the Study:

• To explore the potential of ACT for treating ovarian cancer.
• To identify and discuss strategies for overcoming ACT limitations in solid tumors.

Main Methods:

• Review of existing literature on ACT, including T cells, TILs, TCR-T, and CAR-T cells.
• Analysis of challenges in applying ACT to solid tumors, such as T cell exhaustion and impaired trafficking.
• Exploration of potential solutions to enhance ACT efficacy in the ovarian cancer tumor microenvironment.

Main Results:

• ACT has shown success in hematological malignancies but faces challenges in solid tumors.
• Limitations include poor T cell functionality, persistence, exhaustion, and tumor microenvironment infiltration.
• Strategies to overcome these limitations are crucial for successful ACT in ovarian cancer.

Conclusions:

• ACT holds significant potential for ovarian cancer treatment.
• Addressing T cell dysfunction and improving tumor microenvironment interactions are key to successful ACT implementation.
• Further research into overcoming ACT limitations is warranted for ovarian cancer therapy.